Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-centre, Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of Anti-IgE Monoclonal Antibody to Treat Allergic Asthma Patients Not Adequately Controlled Despite Med/High ICS/LABA.

NCT03468790 is registered in ClinicalTrials.gov with Shanghai Biomabs Pharmaceutical Co., Ltd. as lead sponsor.

NCT NCT03468790
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03468790 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-centre, Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of Anti-IgE Monoclonal Antibody to Treat Allergic Asthma Patients Not Adequately Controlled Despite Med/High ICS/LABA.
Lead sponsor
Shanghai Biomabs Pharmaceutical Co., Ltd.
Phase
Phase 3
Overall status
Completed
Start date
May 9, 2018
Completion date
March 9, 2021
Enrollment
393 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

asthma, allergic